| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041638469 |
| P356 | DOI | 10.1186/AR1736 |
| P932 | PMC publication ID | 2833970 |
| P698 | PubMed publication ID | 15960819 |
| P5875 | ResearchGate publication ID | 7782127 |
| P2093 | author name string | Larry Moreland | |
| P2860 | cites work | Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial | Q77838691 |
| Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig | Q79290408 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Roles of B cells in rheumatoid arthritis | Q33708839 | ||
| Economic burden of rheumatoid arthritis: a systematic review | Q33831406 | ||
| Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity | Q34191742 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 | ||
| A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate | Q35554448 | ||
| An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline | Q41671791 | ||
| Long-term outcome of treating rheumatoid arthritis: results after 20 years | Q41913707 | ||
| Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 | ||
| Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial | Q44205088 | ||
| Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate | Q47784405 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 | ||
| P921 | main subject | rheumatoid arthritis | Q187255 |
| disease-modifying antirheumatic drug | Q810254 | ||
| P304 | page(s) | S2-8 | |
| P577 | publication date | 2005-05-18 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Unmet needs in rheumatoid arthritis. | |
| P478 | volume | 7 Suppl 3 |
| Q37390483 | A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis |
| Q35762912 | APLAR rheumatoid arthritis treatment recommendations. |
| Q42128229 | Abatacept in the treatment of rheumatoid arthritis |
| Q38674546 | An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis |
| Q36204157 | Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. |
| Q37206933 | Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q33725862 | Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. |
Search more.